90 Seconds With… Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)
Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news....
Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news....
Prescient Therapeutics (ASX:PTX) says its cancer-fighting drug candidate has exhibited an excellent safety in an...
The results significantly de-risk the project as PTX continues development of its OmniCAR platform. As...
Tragedy struck the CAR-T space this month with a US company halting a trial of...
Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced another crucial step forward in the development of...
he federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tuesday...
Biotech company Prescient Therapeutics (ASX:PTX) had an important announcement for the market this morning, after strengthening its...
With the number of days left to file March quarterly reports running a little short...
Melbourne biotech company Prescient Therapeutics (ASX:PTX) says a clinical trial evaluating its PTX-200 drug candidate to treat...
StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each...
To stay up to date with Prescient Therapeutics news and events, please register your details.